Pixium Vision S.A. is a French company at the forefront of bioelectronics and brain-machine interface technology, focusing on neuromodulation applications. The company develops the PRIMA System, a sophisticated bionic vision solution aimed at individuals experiencing profound vision loss due to retinal degeneration, specifically the dry atrophic form of Age-related Macular Degeneration (AMD). This system is engineered to combat blindness by effectively replacing the natural function of the eye's photoreceptor cells. It achieves this by electrically stimulating the nerve cells within the inner retina, which then transmit visual information to the brain via the optic nerve. Pixium Vision has established significant collaborative agreements with esteemed institutions such as Stanford University in California, the Institut de la Vision, Moorfields Eye Hospital, the Institute of Ocular Microsurgery, University Hospital, and UPMC. Founded in 2011, the company is headquartered in Paris, France.